In addition, the IGF1R was recently tested as novel therapeutic target in solid malignancies and in multiple myeloma where IGF1R inhibitors appear to overcome bortezomib resistance in the malignant plasma cell [8,9]. This evidence concerns the gene IGF1R and plasma cell myeloma.